DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.

ABSTRACT:

Background

In clinical oncology, systemic 5-fluorouracil (5-FU) and its oral pro-drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with standard doses of 5-FU. DPYD genotyping and measurements of plasma uracil concentration (DPD phenotyping) can be applied as tests for DPD deficiency. In April 2020, the European Medicines Agency recommended pre-treatment DPD testing to reduce the risk of 5-FU-related toxicity.

Objectives

The objective of this study is to present the current evidence for DPD testing in routine oncological practice.

Methods

Two systematic literature searches were performed following the PRISMA guidelines. We identified studies examinin

SUBMITTER: Paulsen NH 

PROVIDER: S-EPMC9826411 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature